Menopause

Short-term exposure to hormone therapy started within 3 years of menopause was not associated with long-term cognitive impairment or benefit, according to data from the KEEPS Continuation study.

In this Healio video exclusive, Joanne Stone, MD, MS, and Susan S. Khalil, MD, discussed highlights from the second annual Mount Sinai Women’s Health Forum, a 1-day conference dedicated to the latest updates in care for midlife women.

Later age at natural menopause may be a risk factor for asthma, potentially due to prolonged estrogen exposure, data from a longitudinal study show.

Women with frequent and persistent hot flashes and night sweats during the menopause transition are at increased risk for developing diabetes compared with women who do not experience vasomotor symptoms, researchers reported.

Interest in menopause and all things related to midlife women’s health continues to grow, and The Menopause Society is expanding to meet the demand.

The FDA accepted a new drug application for elinzanetant, a nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause, according to an industry press release.

Many postmenopausal women self-reported moderate or higher vasomotor symptoms in the primary care setting but remained untreated due to lack of electronic health record documentation, researchers reported.

Women with hypothyroidism receiving levothyroxine treatment experienced similar cognitive decline during menopause as those without thyroid disease, according to data published in Thyroid.

Hormone therapy use markedly declined among postmenopausal women of all ages, races and ethnicities in the U.S. during the past 2 decades, according to findings published in JAMA Health Forum.

Hormonal therapy may delay glaucoma onset in postmenopausal women, with longer duration of treatment linked to later diagnosis of glaucoma, according to a study in Investigative Ophthalmology & Vision Science.